Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Patients Unfit for Standard Chemotherapy
The goal of this clinical research study is to learn if adding the study drug inecalcitol to treatment with decitabine can help to control acute myeloid leukemia (AML) in patients for whom standard chemotherapy is not recommended. The safety of this drug combination will also be studied.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Decitabine,Inecalcitol
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Hybrigenics S.A.
IRB Review and Approval Date: 09/13/2016
Recruitment Status: Open
Projected Accrual: 110
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: